CDE Detailed Report

Disease: Stroke
Subdomain Name: Drugs
CRF: Antithrombotics and Risk Factor Controlling Medications

Displaying 1 - 27 of 27
CDE ID CDE Name Variable Name Definition Short Description Question Text Permissible Values Description Data Type Disease Specific Instructions Disease Specific Reference Population Classification (e.g., Core) Version Number Version Date CRF Name (CRF Module / Guidance) Subdomain Name Domain Name Size Input Restrictions Min Value Max Value Measurement Type External Id Loinc External Id Snomed External Id caDSR External Id CDISC
C58953 Antiplatelet agent stroke discharge prescribe other text AntiplatAgStrkDischrgPrscrbOTH The free-text field related to 'Antiplatelet agent stroke discharge prescribe type', specifying other text The free-text field related to 'Antiplatelet agent stroke discharge prescribe type', specifying other text Other, specify Alphanumeric

No instructions available

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 16:02:18.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C58954 Antihypertensive agent stroke discharge prescribe type AntihyptAgStrkDischrgPrscrbTyp Type(s) of antihypertensive agents prescribed at discharge following stroke Type(s) of antihypertensive agents prescribed at discharge following stroke IF antihypertensive agents prescribed, specify type(s) Beta-blocker (atenolol, metoprolol, propranolol, others);Combined alpha and beta-blocker (carvedilol, labetalol);Calcium channel blocker (amlodipine, diltiazem, nifedipine, verapamil, others);Diuretic (chlorothiazide, hydrochlorothiazide, chlorthalidone, others);ACE-inhibitor (enalaopril, lisinopril, ramipril, others);Angiotensin II receptor blocker (candesartan, losartan, valsartan, others);Alpha blocker (doxazosin, prazosin, terazosin);Central agonist (alpha methyldopa, clonidine, others);Other, specify Beta-blocker (atenolol, metoprolol, propranolol, others);Combined alpha and beta-blocker (carvedilol, labetalol);Calcium channel blocker (amlodipine, diltiazem, nifedipine, verapamil, others);Diuretic (chlorothiazide, hydrochlorothiazide, chlorthalidone, others);ACE-inhibitor (enalaopril, lisinopril, ramipril, others);Angiotensin II receptor blocker (candesartan, losartan, valsartan, others);Alpha blocker (doxazosin, prazosin, terazosin);Central agonist (alpha methyldopa, clonidine, others);Other, specify Alphanumeric

Choose all that apply.

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 16:03:33.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C58955 Antihypertensive agent stroke discharge prescribe other text AntihyptAgStrkDischrgPrscrbOTH The free-text field related to 'Antihypertensive agent stroke discharge prescribe type', specifying other text The free-text field related to 'Antihypertensive agent stroke discharge prescribe type', specifying other text Other, specify Alphanumeric

No instructions available

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 16:12:46.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C58956 Anti diabetic agent stroke discharge prescribe type AntiDbtcAgStrkDischrgPrscrbTyp Type(s) of anti-diabetic agents prescribed at discharge following stroke Type(s) of anti-diabetic agents prescribed at discharge following stroke IF anti-diabetic agents prescribed, specify type(s) Insulin;Amylin analogs (Pramlintide);Sulfonylureas (glimepiride, glipizide, glyburide, others);Meglitinides (nateglinide, repaglinide);Biguanides (metformin);Thiazolidinediones (pioglitazone, rosiglitazone);Alpha-glucosidase inhibitors (acarbose, miglitol);Dipeptidyl peptidase inhibitors (alogliptin, linagliptin, others);Sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin, others);Oral combination drugs;Other, specify Insulin;Amylin analogs (Pramlintide);Sulfonylureas (glimepiride, glipizide, glyburide, others);Meglitinides (nateglinide, repaglinide);Biguanides (metformin);Thiazolidinediones (pioglitazone, rosiglitazone);Alpha-glucosidase inhibitors (acarbose, miglitol);Dipeptidyl peptidase inhibitors (alogliptin, linagliptin, others);Sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin, others);Oral combination drugs;Other, specify Alphanumeric

Choose all that apply.

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 16:13:44.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C58957 Anti diabetic agent stroke discharge prescribe other text AntiDbtcAgStrkDischrgPrscrbOTH The free-text field related to 'Anti diabetic agent stroke discharge prescribe type', specifying other text The free-text field related to 'Anti diabetic agent stroke discharge prescribe type', specifying other text Other, specify Alphanumeric

No instructions available

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 16:34:09.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C58845 Discharge origin location type DischargeOriginLocTyp The type of origin location that is discharging the participant/subject The type of origin location that is discharging the participant/subjec Specify discharging location Intensive Inpatient rehabilitation facility (IRF) including distinct rehabilitation units of a hospital: three hours or greater of therapy per day;Acute hospital;Medicare certified long-term care hospital (LTCH);Hospice- home or medical facility providing hospice level of care;Other not defined above:;Skilled nursing facility (SNF)/ subacute rehab: less than two hours a day of therapy Intensive Inpatient rehabilitation facility (IRF) including distinct rehabilitation units of a hospital: three hours or greater of therapy per day;Acute hospital;Medicare certified long-term care hospital (LTCH);Hospice- home or medical facility providing hospice level of care;Other not defined above:;Skilled nursing facility (SNF)/ subacute rehab: less than two hours a day of therapy Alphanumeric

No instructions available

 No references available Adult;Pediatric Supplemental 1.00 2020-05-17 18:41:28.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Single Pre-Defined Value Selected
C58958 Lipid lower agent stroke discharge prescribe type LipidLowAgStrkDischrgPrscrbTyp Type(s) of lipid lowering agents prescribed at discharge following stroke Type(s) of lipid lowering agents prescribed at discharge following stroke IF lipid lowering agents prescribed, specify type(s) Statin (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin);PCSK9 inhibitors (alirocumab, evolocumab);Selective cholesterol absorption inhibitors (ezetimibe);Bile acid sequestrants (cholestyramine, colestipol, colesevelam);Fibrates (gemfibrozil, fenofibrate, clofibrate);Niacin;Omega-3 fatty acid ethyl esters (Lovaza, Vascepa);Marine-derived omega-3 polyunsaturated fatty acids;Other, specify Statin (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin);PCSK9 inhibitors (alirocumab, evolocumab);Selective cholesterol absorption inhibitors (ezetimibe);Bile acid sequestrants (cholestyramine, colestipol, colesevelam);Fibrates (gemfibrozil, fenofibrate, clofibrate);Niacin;Omega-3 fatty acid ethyl esters (Lovaza, Vascepa);Marine-derived omega-3 polyunsaturated fatty acids;Other, specify Alphanumeric

Choose all that apply.

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 16:35:08.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C58846 Discharge origin location other text DischargeOriginLocOTH The free-text field related to 'Discharge origin location type', specifying other text The free-text field related to 'Discharge origin location type', specifying other text Other not defined above Alphanumeric

No instructions available

 No references available Adult;Pediatric Supplemental 1.00 2020-05-18 07:54:34.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C58959 Lipid lower agent stroke discharge prescribe other text LipidLowAgStrkDischrgPrscrbOTH The free-text field related to 'Lipid lower agent stroke discharge prescribe type', specifying other text The free-text field related to 'Lipid lower agent stroke discharge prescribe type', specifying other text Other, specify Alphanumeric

No instructions available

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 16:40:56.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C58949 Medication stroke discharge prescribe category MedctnStrkDischrgPrscrbCat Class(es) of medications the participant/subject was prescribed at discharge following stroke Class(es) of medications the participant/subject was prescribed at discharge following stroke Which class(es) of medications was the participant/subject prescribed at discharge Anticoagulant agents;Antiplatelet agents;Antihypertensive agents;Anti-diabetic agents;Lipid lowering agents Anticoagulant agents;Antiplatelet agents;Antihypertensive agents;Anti-diabetic agents;Lipid lowering agents Alphanumeric

Choose all that apply.

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 15:34:45.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C58960 Antithrombotic therapy not prescribed serious side effect text AntithromThrNotPrsSrSdeEfctTxt The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying serious side effect to medication text The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying serious side effect to medication text Serious side effect to medication, specify Alphanumeric

Choose all that apply. If reasons are not mentioned in the context of antithrombotics, do not make inferences (e.g., do not assume that antithrombotics are not being prescribed because of a bleeding disorder unless documentation explicitly states so).

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (© 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry Adult;Pediatric Supplemental 1.00 2020-07-29 16:42:04.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C58950 Anticoagulant agent stroke discharge prescribe type AnticoagAgStrkDischrgPrscrbTyp Type(s) of anticoagulant agents prescribed at discharge following stroke Type(s) of anticoagulant agents prescribed at discharge following stroke IF anticoagulant agents prescribed, specify type(s) Other, specify;Low molecular weight heparin (LMWH) (Enoxaparin, others);Warfarin (Coumadin);Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) Other, specify;Low molecular weight heparin (LMWH) (Enoxaparin, others);Warfarin (Coumadin);Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) Alphanumeric

Choose all that apply.

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 15:42:35.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C58951 Anticoagulant agent stroke discharge prescribe other text AnticoagAgStrkDischrgPrscrbOTH The free-text field related to 'Anticoagulant agent stroke discharge prescribe type', specifying other text The free-text field related to 'Anticoagulant agent stroke discharge prescribe type', specifying other text Other, specify Alphanumeric

No instructions available

 No references available Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 15:54:08.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C58952 Antiplatelet agent stroke discharge prescribe type AntiplatAgStrkDischrgPrscrbTyp Type(s) of antiplatelet agents prescribed at discharge following stroke Type(s) of antiplatelet agents prescribed at discharge following stroke IF antiplatelet agents prescribed, specify type(s) Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Cilostazol;Other, specify Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Cilostazol;Other, specify Alphanumeric

Choose all that apply.

 Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH [published correction appears in J Thromb Haemost. 2015;13(8):1539]. J Thromb Haemost. 2015;13(6):1154-1156.<br /><br />Kim BJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LKS, Yu S, Hwang YH, Lee JS, Lee J, Rha JH, Heo SH, Ahn SH, Seo WK, Park JM, Lee JH, Kwon JH, Sohn SI, Jung JM, Navarro JC, Kim HY, Kim EG, Kim S, Cha JK, Park MS, Nam HS, Kang DW; PICASSO Investigators. Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial. Stroke. 2020 Mar;51(3):931-937. Adult;Pediatric Supplemental-Highly Recommended 1.00 2020-07-29 15:56:47.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C18984 Anticoagulant agent in hospital other text AnticoagAgentInHospOTH The free-text field related to 'Anticoagulant agent in hospital type', specifying other text The free-text field related to 'Anticoagulant agent in hospital type', specifying other text Other, specify Alphanumeric

Choose all that apply.

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (&copy; 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry Adult;Pediatric Supplemental-Highly Recommended 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C18985 Antiplatelet agent in hospital other text AntiplatAgentInHospOTH The free-text field related to 'Antiplatelet agent in hospital type', specifying other text The free-text field related to 'Antiplatelet agent in hospital type', specifying other text Other, specify Alphanumeric

Choose all that apply.

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (&copy; 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry Adult;Pediatric Supplemental-Highly Recommended 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C18986 Extracranial venous thromboembolism other text ExtraCranVenThromOTH The free-text field related to 'Extracranial venous thromboembolism type', specifying other text The free-text field related to 'Extracranial venous thromboembolism type', specifying other text Other, specify Alphanumeric

Choose all that apply.

 No references available Adult;Pediatric Supplemental 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C14629 Anticoagulant agent in hospital indicator AnticoagAgentInHospInd Whether the participant/subject received anticoagulant agents during the acute hospital stay, not including venous prophylaxis dose Unfractionated heparin, LMW heparin, etc Whether the participant/subject received anticoagulant agents during the acute hospital stay, not including venous prophylaxis dose Unfractionated heparin, LMW heparin, etc. Did the participant/subject receive anticoagulant agents Yes;No;Unknown Yes;No;Unknown Alphanumeric

Choose one

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (&copy; 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en Adult;Pediatric Supplemental-Highly Recommended 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Single Pre-Defined Value Selected
C18987 Extracranial venous thromboembolism prophylaxis other text ExtraCranVenThromProphylOTH The free-text field related to 'Extracranial venous thromboembolism prophylaxis type', specifying other text The free-text field related to 'Extracranial venous thromboembolism prophylaxis type', specifying other text Other, specify Alphanumeric

Choose all that apply.

 CMS/ The Joint Commission: SCIP-VTE-1, SCIP-VTE-2; The Joint Commission Only: STK-1, VTE-1 Adult;Pediatric Supplemental 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C14630 Anticoagulant agent in hospital type AnticoagAgentInHospTyp Type(s) of anticoagulant agents received during the acute hospital stay Type(s) of anticoagulant agents received during the acute hospital stay IF YES, type(s) of anticoagulant agents received Unfractionated heparin IV;Full dose LMW heparin (Enoxaparin, Others);Warfarin (Coumadin);Other, specify;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) Unfractionated heparin IV;Full dose LMW heparin (Enoxaparin, Others);Warfarin (Coumadin);Other, specify;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) Alphanumeric

Choose all that apply.

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (&copy; 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry Adult;Pediatric Supplemental-Highly Recommended 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C18988 Antithrombotic therapy not prescribed other text AntithromTherNotPresOTH The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying other text The free-text field related to 'Antithrombotic therapy not prescribed reason', specifying other text Other, specify Alphanumeric

Choose all that apply. If reasons are not mentioned in the context of antithrombotics, do not make inferences (e.g., do not assume that antithrombotics are not being prescribed because of a bleeding disorder unless documentation explicitly states so).

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (&copy; 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry Adult;Pediatric Supplemental 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data 4000

Free-Form Entry
C14631 Antiplatelet agent in hospital indicator AntiplatelAgentInHospInd Whether the participant/subject received antiplatelet agents during the acute hospital stay Whether the participant/subject received antiplatelet agents during the acute hospital stay Did the participant/subject receive antiplatelet agents Yes;No;Unknown Yes;No;Unknown Alphanumeric

Choose one

 No references available Adult;Pediatric Supplemental-Highly Recommended 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Single Pre-Defined Value Selected
C14632 Antiplatelet agent in hospital type AntiplatAgentInHospTyp Type(s) of antiplatelet agents received during the acute hospital stay Type(s) of antiplatelet agents received during the acute hospital stay IF YES, type(s) of antiplatelet agents received Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Other, specify;Cilostazol Aspirin;Aspirin/Dipyridamole (in separate formulations or as Aggrenox);Clopidogrel (Plavix);Other, specify;Cilostazol Alphanumeric

Choose all that apply.

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (&copy; 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry<br /><br />Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH [published correction appears in J Thromb Haemost. 2015;13(8):1539]. J Thromb Haemost. 2015;13(6):1154-1156.<br /><br />Kim BJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LKS, Yu S, Hwang YH, Lee JS, Lee J, Rha JH, Heo SH, Ahn SH, Seo WK, Park JM, Lee JH, Kwon JH, Sohn SI, Jung JM, Navarro JC, Kim HY, Kim EG, Kim S, Cha JK, Park MS, Nam HS, Kang DW; PICASSO Investigators. Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial. Stroke. 2020 Mar;51(3):931-937. Adult;Pediatric Supplemental-Highly Recommended 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C14633 Extracranial venous thromboembolism indicator ExtraVenThromInd Whether the participant/ subject was diagnosed with an extracranial venous thromboembolism (VTE) Whether the participant/ subject was diagnosed with an extracranial venous thromboembolism (VTE) Was the participant/subject diagnosed with VTE Yes;No;Unknown Yes;No;Unknown Alphanumeric

Choose one

 No references available Adult;Pediatric Supplemental 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Single Pre-Defined Value Selected
C14634 Extracranial venous thromboembolism type ExtraCranVenThromTyp Type(s) of extracranial venous thromboembolism (VTE) diagnosed with Type(s) of extracranial venous thromboembolism (VTE) diagnosed with IF YES, diagnosis with which type(s) Deep venous thrombosis (DVT);Pulmonary embolism;Other, specify Deep venous thrombosis (DVT);Pulmonary embolism;Other, specify Alphanumeric

Choose all that apply.

 No references available Adult;Pediatric Supplemental 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C14635 Extracranial venous thromboembolism prophylaxis type ExtraCranVenThromProphylTyp Type(s) of extracranial venous thromboembolism (VTE) prophylaxis used Type(s) of extracranial venous thromboembolism (VTE) prophylaxis used IF YES, type(s) of VTE prophylaxis used Low dose unfractionated heparin (LDUH);Low molecular weight heparin (LMWH);Intermittent pneumatic compression devices (IPC);Other, specify;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) "regular" heparin;enoxaparin, dalteparin, nadroparin, danaparoid, heparinoids, etc.;;;Direct thrombin inhibitor (Lepirudin, Desirudin, Bivalirudin, Argatroban, Dabigatran);Factor Xa inhibitor (Apixaban, Betrixaban, Edoxaban, Rivaroxaban, Fondaparinux) Alphanumeric

Choose all that apply.

 CMS/ The Joint Commission: SCIP-VTE-1, SCIP-VTE-2; The Joint Commission Only: STK-1, VTE-1 Adult;Pediatric Supplemental 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
C14638 Antithrombotic therapy not prescribed reason AntithromTherNotPresRsn Reason(s) for not prescribing antithrombotic therapy (i.e., no anticoagulant or antiplatelet agents), documented by a physician, advance practice nurse or physician assistant Reason(s) for not prescribing antithrombotic therapy (i.e., no anticoagulant or antiplatelet agents), documented by a physician, advance practice nurse or physician assistan Reason(s) antithrombotic therapy was not prescribed at discharge Allergy to aspirin, clopidogrel, dipyridamole, cilostazol, warfarin, direct thrombin inhibitor, factor Xa inhibitor or heparin (history or current);Patient/Family refused;Risk for bleeding;Discontinued due to bleeding;Serious side effect to medication, specify;Terminal illness/Comfort measures only;Other, specify Allergy to aspirin, clopidogrel, dipyridamole, cilostazol, warfarin, direct thrombin inhibitor, factor Xa inhibitor or heparin (history or current);Patient/Family refused;Risk for bleeding;Discontinued due to bleeding;Serious side effect to medication, specify;Terminal illness/Comfort measures only;Other, specify Alphanumeric

Choose all that apply. If reasons are not mentioned in the context of antithrombotics, do not make inferences (e.g., do not assume that antithrombotics are not being prescribed because of a bleeding disorder unless documentation explicitly states so).

 American Heart/American Stroke Association. (2018). Get With The Guidelines (GWTG) Stroke Patient Management Tool Coding Instructions (&copy; 2018, American Heart/American Stroke Association). Available at: https://www.heart.org/-/media/files/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/stroke-fact-sheet_-final_ucm_501842.pdf?la=en; Paul Coverdell National Acute Stroke Registry Adult;Pediatric Supplemental 3.00 2013-06-21 00:00:00.0 Antithrombotics and Risk Factor Controlling Medications Drugs Treatment/Intervention Data

Multiple Pre-Defined Values Selected
CSV